Predictive Biosciences raises $21.8M for cancer diagnostic tech
Predictive Biosciences, a company that hopes to improve the way cancer is diagnosed and monitored, announced that it brought in $21.8 million in second-round financing led by New Enterprise Associates and including contributions from Kaiser Permanente Ventures, Flybridge Venture Capital and Highland Capital Partners. This brings the company’s VC total up to $31.7 million since its inception in 2006.
The Lexington, Mass.-based company plans to use its new funds to complete clinical studies and launch new trials to see if biomarkers in urine can be used to accurately diagnose and track the growth of cancer. If results are promising, this technology may make constant blood tests and painful biopsies a thing of the past. The initial focus of the research will be bladder cancer, but scientists say that the urine tests should be able to accurately detect the presence of prostate, breast, colorectal and other types of cancer, according to VentureWire.
Next Story: Even in tough times, Google beats analysts’ expectations
Previous Story: Microsoft sued for allegedly covering up Xbox 360 defects
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.
With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.